Sugi Predict

Sugi Predict / Compounds / SCHEMBL1729033

SCHEMBL1729033

SCHEMBL1729033

CC[C@H](N)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 3/20 0.52
▸ PDE2A O00408 3/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.41
▸ TACR1 P25103 3/20 0.41
▸ KIF11 P52732 2/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ CACNA1C Q13936 2/20 0.39
▸ SLC6A2 P23975 2/20 0.39
▸ SLC6A3 Q01959 2/20 0.39
▸ CACNA1F O60840 1/20 0.39
▸ CACNA1D Q01668 1/20 0.39
▸ CACNA1S Q13698 1/20 0.39
▸ KCNK2 O95069 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ MC4R P32245 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3171890 1.00 SLC6A4 (0.52) SLC6A4PDE2ATAAR1TACR1KIF11
SCHEMBL1727842 1.00 SLC6A4 (0.52) SLC6A4PDE2ATAAR1TACR1KIF11
Hydrochloric Acid SCHEMBL17766990 0.98 SLC6A4 (0.50) SLC6A4PDE2ATAAR1TACR1KIF11
Hydrochloric Acid SCHEMBL20791454 0.98 SLC6A4 (0.50) SLC6A4PDE2ATAAR1TACR1KIF11
Hydrochloric Acid SCHEMBL4936793 0.98 SLC6A4 (0.50) SLC6A4PDE2ATAAR1TACR1KIF11
SCHEMBL17574500 0.86 SLC6A4 (0.50) SLC6A4PDE2ATACR1CACNA1CCACNA1F
SCHEMBL3602797 0.84 PDE2A (0.43) SLC6A4PDE2ATAAR1TACR1KIF11
SCHEMBL906156 0.84 PDE2A (0.43) SLC6A4PDE2ATAAR1TACR1KIF11
SCHEMBL3595268 0.84 PDE2A (0.43) SLC6A4PDE2ATAAR1TACR1KIF11
SCHEMBL23092069 0.82 SLC6A4 (0.70) SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240245691-A1 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION SITRYX THERAPEUTICS LIMITED (GB) 2024-07-25 — — US disclosed
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2024-05-16 — — US disclosed
EP-4330231-A1 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION Sitryx Therapeutics Limited (GB) 2024-03-06 — — EP disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 — — US disclosed
WO-2022229617-A1 2-METHYLENE-4-OXO-BUTANOIC ACID DRIVATIVES FOR THE TREATMENT OF INFLAMMATION SITRYX THERAPEUTICS LIMITED (GB) 2022-11-03 — — WO disclosed
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2022-09-08 — — US disclosed
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2022-02-22 — — US disclosed
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2022-02-22 — — US disclosed
US-10723720-B2 Bisamide sarcomere activating compounds and uses therof AMGEN INC. (US) 2020-07-28 — — US disclosed
US-10723720-B2 Bisamide sarcomere activating compounds and uses therof AMGEN INC. (US) 2020-07-28 — — US disclosed
EP-2036881-B1 METHOD FOR PRODUCING OPTICALLY ACTIVE 1-(FLUORO-, TRIFLUOROMETHYL- OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVE CENTRAL GLASS CO LTD (JP) 2013-09-25 — — EP disclosed
EP-1530562-B1 OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME CENTRAL GLASS CO LTD (JP) 2011-11-30 — — EP disclosed
US-7985880-B2 Method for producing optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy-substituted phenyl) alkylamine N-monoalkyl derivative CENTRAL GLASS COMPANY, LIMITED (JP) 2011-07-26 — — US disclosed
US-20090326272-A1 Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative CENTRAL GLASS COMPANY, LIMITED (JP) 2009-12-31 — — US disclosed
EP-2036881-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE 1-(FLUORO-, TRIFLUOROMETHYL- OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVE Central Glass Co., Ltd. (JP) 2009-03-18 — — EP disclosed
US-7368609-B2 Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same CENTRAL GLASS COMPANY, LIMITED (JP) 2008-05-06 — — US disclosed
WO-2008011392-A2 PROLINE UREA CCR1 ANTAGONISTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR INFLAMMATION LIGAND PHARMACUETICALS INCORPORATED (US) 2008-01-24 — — WO disclosed
US-20070142670-A1 Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same CENTRAL GLASS CO., LTD. (JP) 2007-06-21 — — US disclosed
US-7186865-B2 Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture CENTRAL GLASS COMPANY, LIMITED (JP) 2007-03-06 — — US disclosed
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same CENTRAL GLASS COMPANY, LIMITED (JP) 2004-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326272-A1 Method for Producing Optically Active 1-(Fluoro-, Trifluoromethyl- or Trifluoromethoxy-Substituted Phenyl) Alkylamine N-Monoalkyl Derivative NAT1, MAOA, HNMT SLC6A4 1197/4885PDE2A 1320/4885TAAR1 207/4885
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 SLC6A4 2425/4885PDE2A 212/4885TAAR1 4398/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 SLC6A4 2425/4885PDE2A 212/4885TAAR1 4398/4885
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 SLC6A4 2425/4885PDE2A 212/4885TAAR1 4398/4885
US-20040235961-A1 Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same NAT1, PNMT, AFF1 SLC6A4 1333/4885PDE2A 1807/4885TAAR1 161/4885
US-20240245691-A1 2-METHYLENE-4-OXO-BUTANOIC ACID DERIVATIVES FOR THE TREATMENT OF INFLAMMATION HCAR2, NFKBIA, TNF SLC6A4 4698/4885PDE2A 976/4885TAAR1 3007/4885
US-10723720-B2 Bisamide sarcomere activating compounds and uses therof TNNI3, TNNT2, TNNC1 SLC6A4 2593/4885PDE2A 971/4885TAAR1 3382/4885
US-20070142670-A1 Optically active 1-(fluoro-, trifluoromethyl- or trifluoromethoxy- substituted phenyl)alkylamine N-monoalkyl derivatives and process for producing same NAT1, AFF1, PNMT SLC6A4 1394/4885PDE2A 1623/4885TAAR1 105/4885
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 SLC6A4 2425/4885PDE2A 212/4885TAAR1 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.